PL1691827T3 - Zastosowanie peptydów pochodzących z łańcucha beta ludzkiego fibrynogenu do leczenia wstrząsu - Google Patents

Zastosowanie peptydów pochodzących z łańcucha beta ludzkiego fibrynogenu do leczenia wstrząsu

Info

Publication number: PL1691827T3
Authority: PL; Poland
Prior art keywords: sub; moiety; shock; treatment; peptide
Prior art date: 2004-06-25

Application number

PL05752350T

Other languages

English (en)

Inventor

Peter Petzelbauer

Kai Zacharowski

Original Assignee

Fibrex Medical Res & Development Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-06-25

Filing date

2005-06-24

Publication date

2010-01-29

2004-06-25 Priority claimed from AT0108704A external-priority patent/AT414097B/de

2005-01-13 Priority claimed from AT0004005A external-priority patent/AT501263B1/de

2005-06-24 Application filed by Fibrex Medical Res & Development Gmbh filed Critical Fibrex Medical Res & Development Gmbh

2010-01-29 Publication of PL1691827T3 publication Critical patent/PL1691827T3/pl

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
230000035939 shock Effects 0.000 title abstract 2
102000004196 processed proteins & peptides Human genes 0.000 title 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 abstract 2
102000009123 Fibrin Human genes 0.000 abstract 1
108010073385 Fibrin Proteins 0.000 abstract 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
102000008790 VE-cadherin Human genes 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
230000004071 biological effect Effects 0.000 abstract 1
108010018828 cadherin 5 Proteins 0.000 abstract 1
125000004432 carbon atom Chemical group C* 0.000 abstract 1
229950003499 fibrin Drugs 0.000 abstract 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
229920006395 saturated elastomer Polymers 0.000 abstract 1
229930195734 saturated hydrocarbon Natural products 0.000 abstract 1
229930195735 unsaturated hydrocarbon Natural products 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Zoology (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL05752350T 2004-06-25 2005-06-24 Zastosowanie peptydów pochodzących z łańcucha beta ludzkiego fibrynogenu do leczenia wstrząsu PL1691827T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
AT0108704A AT414097B (de)	2004-06-25	2004-06-25	Pharmazeutische zubereitung zur behandlung von schock
AT0004005A AT501263B1 (de)	2005-01-13	2005-01-13	Pharmazeutische zubereitung zur behandlung von schock
PCT/AT2005/000228 WO2006000007A1 (de)	2004-06-25	2005-06-24	Verwendung von peptiden, die aus der a alpha oder der b beta kette des humanen fibrinogens abgeleitet wurden, zur behandlung von schock
EP05752350A EP1691827B1 (de)	2004-06-25	2005-06-24	Verwendung von peptiden, die aus der b beta kette des humanen fibrinogens abgeleitet wurden, zur behandlung von schock

Publications (1)

Publication Number	Publication Date
PL1691827T3 true PL1691827T3 (pl)	2010-01-29

Family

ID=35058593

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL05752350T PL1691827T3 (pl)	2004-06-25	2005-06-24	Zastosowanie peptydów pochodzących z łańcucha beta ludzkiego fibrynogenu do leczenia wstrząsu

Country Status (19)

Country	Link
US (1)	US20080249006A1 (pl)
EP (1)	EP1691827B1 (pl)
JP (1)	JP2008503503A (pl)
AT (1)	ATE439856T1 (pl)
AU (1)	AU2005256121B2 (pl)
BR (1)	BRPI0506148A (pl)
CA (1)	CA2544676A1 (pl)
CY (1)	CY1109631T1 (pl)
DE (1)	DE502005007926D1 (pl)
DK (1)	DK1691827T3 (pl)
EA (1)	EA008799B1 (pl)
ES (1)	ES2331958T3 (pl)
HR (1)	HRP20090618T1 (pl)
IL (1)	IL173969A (pl)
NZ (1)	NZ545634A (pl)
PL (1)	PL1691827T3 (pl)
PT (1)	PT1691827E (pl)
SI (1)	SI1691827T1 (pl)
WO (1)	WO2006000007A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT502987A1 (de)	2005-12-23	2007-07-15	Fibrex Medical Res & Dev Gmbh	Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen
US20080004220A1 (en)	2006-02-23	2008-01-03	Fibrex Medical Research & Development Gmbh	Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
EP1987062B1 (en) *	2006-02-23	2011-06-22	Fibrex Medical Research & Development GmbH	Peptides and peptide derivatives as well as pharmaceutical compositions containing the same
WO2007095659A1 (de) *	2006-02-23	2007-08-30	Fibrex Medical Research & Development Gmbh	Peptide und peptid-derivate, herstellun derselben sowie deren verwendung zur herstellung eines therapeutisch und/oder präventiv wirkenden arzneimittels
EP2193370A2 (en) *	2007-09-24	2010-06-09	Fibrex Medical Research & Development GmbH	Methods of screening for compounds having anti-inflammatory activity
WO2009096502A1 (ja) *	2008-01-31	2009-08-06	Japan As Represented By President Of National Center Of Neurology And Psychiatry	うつ病およびうつ状態のマーカーおよびそれを用いた検出・診断
US7884074B2 (en)	2008-05-15	2011-02-08	Ikaria Development Subsidiary Two, LLC	Compounds and methods for prevention and/or treatment of inflammation using the same
US8088890B2 (en) *	2008-09-26	2012-01-03	Fibrex Medical Research & Development Gmbh	Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
WO2010043444A2 (en) *	2008-10-15	2010-04-22	Fibrex Medical Research & Development Gmbh	Pharmaceutical preparation for the treatment and/or prevention of ischemia/reperfusion injury and the sequels thereof
US12128102B2 (en)	2016-03-08	2024-10-29	Takeda Pharmaceutical Company Limited	Constrained conditionally activated binding proteins
IL302613B2 (en)	2017-09-08	2025-04-01	Maverick Therapeutics Inc	Binding proteins are activated under limited conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5965107A (en) *	1992-03-13	1999-10-12	Diatide, Inc.	Technetium-99m labeled peptides for imaging
DE19729591A1 (de) *	1997-07-10	1999-02-11	Therasorb Medizinische Systeme	Mittel zur Behandlung und/oder Prophylaxe von Mikrozirkulationsstörungen
AU2002221316A1 (en) *	2000-12-12	2002-06-24	Fibrex Medical Research & Development Gmbh	Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic medicament
ATE345788T1 (de) *	2001-03-06	2006-12-15	Dorian Bevec	Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieber
EP1987062B1 (en) *	2006-02-23	2011-06-22	Fibrex Medical Research & Development GmbH	Peptides and peptide derivatives as well as pharmaceutical compositions containing the same

2005
- 2005-06-24 CA CA002544676A patent/CA2544676A1/en not_active Abandoned
- 2005-06-24 DK DK05752350T patent/DK1691827T3/da active
- 2005-06-24 EP EP05752350A patent/EP1691827B1/de not_active Expired - Lifetime
- 2005-06-24 HR HR20090618T patent/HRP20090618T1/hr unknown
- 2005-06-24 AT AT05752350T patent/ATE439856T1/de active
- 2005-06-24 SI SI200530842T patent/SI1691827T1/sl unknown
- 2005-06-24 BR BRPI0506148-2A patent/BRPI0506148A/pt not_active IP Right Cessation
- 2005-06-24 WO PCT/AT2005/000228 patent/WO2006000007A1/de not_active Ceased
- 2005-06-24 AU AU2005256121A patent/AU2005256121B2/en not_active Ceased
- 2005-06-24 PT PT05752350T patent/PT1691827E/pt unknown
- 2005-06-24 JP JP2007516870A patent/JP2008503503A/ja active Pending
- 2005-06-24 NZ NZ545634A patent/NZ545634A/en not_active IP Right Cessation
- 2005-06-24 PL PL05752350T patent/PL1691827T3/pl unknown
- 2005-06-24 US US10/596,103 patent/US20080249006A1/en not_active Abandoned
- 2005-06-24 EA EA200600561A patent/EA008799B1/ru not_active IP Right Cessation
- 2005-06-24 ES ES05752350T patent/ES2331958T3/es not_active Expired - Lifetime
- 2005-06-24 DE DE502005007926T patent/DE502005007926D1/de not_active Expired - Lifetime
2006
- 2006-02-27 IL IL173969A patent/IL173969A/en not_active IP Right Cessation
2009
- 2009-11-13 CY CY20091101198T patent/CY1109631T1/el unknown

Also Published As

Publication number	Publication date
IL173969A0 (en)	2006-07-05
JP2008503503A (ja)	2008-02-07
AU2005256121A8 (en)	2008-08-21
AU2005256121B2 (en)	2011-03-03
EA008799B1 (ru)	2007-08-31
CA2544676A1 (en)	2006-01-05
IL173969A (en)	2011-06-30
NZ545634A (en)	2009-09-25
ATE439856T1 (de)	2009-09-15
HK1093308A1 (zh)	2007-03-02
EA200600561A1 (ru)	2006-08-25
US20080249006A1 (en)	2008-10-09
CY1109631T1 (el)	2014-08-13
SI1691827T1 (sl)	2010-01-29
DK1691827T3 (da)	2009-12-14
BRPI0506148A (pt)	2006-10-24
WO2006000007A1 (de)	2006-01-05
DE502005007926D1 (de)	2009-10-01
ES2331958T3 (es)	2010-01-21
AU2005256121A1 (en)	2006-04-27
HRP20090618T1 (hr)	2010-01-31
EP1691827A1 (de)	2006-08-23
EP1691827B1 (de)	2009-08-19
PT1691827E (pt)	2009-11-23

Publication	Publication Date	Title
CY1109631T1 (el)	2014-08-13	Χρησιμοποιηση πεπτιδιων, τα οποια εχουν παραχθει απο την αα- ή ββ-αλυσιδα του ανθρωπινου ινωδογονου, για τη θεραπεια σοκ
WO2009004315A8 (en)	2009-07-16	Isolated peptides and uses thereof
UA103154C2 (uk)	2013-09-25	Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його
IN2014CN02050A (pl)	2015-05-29
EP2267015A3 (en)	2011-04-20	Binding polypeptides for B lymphocyte stimulator protein (BLyS)
NZ593815A (en)	2013-05-31	Tissue factor pathway inhibitor (tfpi) inhibitors and methods of use
AU2002217010A1 (en)	2002-05-21	Peptides, the production and use thereof for binding immunoglobulins
WO2006113681A3 (en)	2010-09-02	Plant-derived elastin binding protein ligands and methods of using the same
DE602005020165D1 (de)	2010-05-06	Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
MX2008009493A (es)	2008-10-03	Peptido novedoso y uso del mismo.
MXPA03005218A (es)	2004-12-03	Peptidos y/o proteinas y uso de los mismos para la produccion de un medicamento terapeutico y/o profilactico.
DE602006017667D1 (de)	2010-12-02	Cysteinhaltiges peptid-tag zur stellenspezifischen konjugation von proteinen
ATE362487T1 (de)	2007-06-15	N-substituierte l-aminosäuren enthaltende peptide,zur prävention der beta-strang assoziation
WO2007029262A3 (en)	2009-04-30	Compositions and methods using same for the detection of viruses
UA91497C2 (ru)	2010-08-10	ПРИМЕНЕНИЕ ПЕПТИДОВ, ВЫДЕЛЕННЫХ ИЗ ЦЕПИ Bb ЧЕЛОВЕЧЕСКОГО ФИБРИНОГЕНА, ДЛЯ ЛЕЧЕНИЯ ШОКА
NO20040905L (no)	2004-05-26	Peptidaktige forbindelser som selektivt binder til P-selektin, farmasoytiske preparater som inneholder peptidforbindelsene og nukleinsyrer som koder for dem.
ATE538806T1 (de)	2012-01-15	Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren
EP3771719A8 (en)	2021-04-14	A peptide binding to tau-protein
NZ593086A (en)	2013-02-22	Isolated peptide binding to human leukocyte antigen (HLA) and having cytotoxic T lymphocyte (CTL) inducibility
WO2007066018A3 (fr)	2007-07-26	Peptides qui peuvent se lier a la proteine nef et leurs applications pharmaceutiques
AU2003288320A1 (en)	2004-05-04	Peptides binding the phosphatase 2a protein and polynucleotides encoding same
GB9901710D0 (en)	1999-03-17	Peptide inhibitors
WO2004013167A3 (en)	2004-05-06	Purified polypeptides from enterococcus faecalis
WO2005087809B1 (en)	2006-02-02	Peptides from vitronectin and their therapeutic exploitation for osteoblast adhesion
SG170757A1 (en)	2011-05-30	Polypeptide having esterase activity and recombinant esterase and use thereof